Its no wonder, then, that when talking about weight loss today, discussion is dominated by the new GLP-1 (glucagon-like peptide-1) drugs
Half Life
We first assembled two separate base cohorts of new users of the drug classes of interest (GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide (except the 3 mg/0.5 mL formulation indicated for weight loss), lixisenatide, semaglutide) and SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin))
If nausea persists or interferes with your routine, discuss switching to the alternate timing with your PlexusDx clinical teamthey can also evaluate whether your dose is appropriate or whether your genetic profile suggests an adjustment
As treatment options continue to grow, the future of care is becoming more individualized and responsive to the needs of people affected by obesity